There was a flurry of activity on social media in June when John Erickson et al. published in Biotechnology and Bioengineering on end-to-end collaboration to transform development and manufacturing of biopharmaceuticals.
i3 is our premier annual customer event where we bring together science, IT and R&D business leaders to share ideas, create new insights and advance innovation!
In a recent survey of biopharma development teams, participants reported spending an average of 1 day each week, or 20% of their time on data administration.
Managing bioprocess data is a complex challenge even if you run just a few experiments per month. With HTPD this can quickly scale up to hundreds of automated, parallelized experiments. Used effectively as part of a BioPharma Lifecycle Management strategy, the data generated from HTPD can accelerate development by supporting better decision making and reducing timelines.
In this webinar IDBS will share how an innovative approach to biopharma lifecycle management supports true QbD and can accelerate development to bring products to market faster.
One of the lasting legacies of the COVID-19 pandemic is heightened awareness of manufacturing challenges and supply chain vulnerabilities in the biopharma industry and the impact this can have on public health. Issues have occurred at every stage of the supply chain, from the availability of raw materials to quality concerns with active pharmaceutical ingredients (APIs), and finished dosage forms and restrictive cold chain requirements.
In a recent Forbes article, Danaher’s Chief Science officer, Jose-Carlos Gutierrez-Ramos, described the impact of the COVID-19 pandemic as follows:“I believe the biopharma business model has fundamentally changed.
VideoHow many times a day do you walk across the lab to get to your ELN and record your data? Whatever the number, it’s still too many. It pulls you away from your bench, away from the science. It’s a…
eBookRegardless of the industry an organization operates in, remaining compliant with ever-changing legislation is an important aspect of corporate operations. For businesses that focus on research and development however, it’s essential. This is because of the frequently high-risk…
eBook’This is how we’ve always done it’ is a very dangerous statement to be made within any business, especially in R&D. This one line illustrates that a team may have fallen into the trap of relying on old processes which…